Announcing Our Next Symposium:

September 15-17, 2008 - New York City
Click here for details.
In the five decades since its inception, the Cancer Research Institute has established itself as a leader in the immunology and tumor immunology research communities. As a well-known and respected organization within these scientific communities, CRI has the ability to convene the world's top immunologists and tumor immunologists whenever there is need to discuss breaking developments or significant challenges in these two fields.
We regularly host conferences and other forums that give dedicated researchers and clinicians an opportunity to gain a comprehensive overview of the immunological landscape, exchange ideas and findings, and advance the field.
The first meeting, Frontiers of Immunology and Cancer Immunology, was held in 1993 and was dedicated to Dr. William B. Coley, commemorating his first clinical use of bacterial vaccines to treat cancer. Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the potential and problems in the development of cancer immunotherapies.
Past Symposia:
Cancer and HIV Vaccines 2007: Shared Lessons
The Institute's 15th annual symposium, Cancer and HIV Vaccines 2007: Shared Lessons , took place October 4-6, 2007, in New York City. Cancer and HIV vaccine researchers from around the world and representatives from industry and health research funding organizations gathered to share and discuss data from the latest clinical and laboratory studies aimed at developing preventive and therapeutic vaccines for both diseases. The conference was the only forum specifically intended to bring cancer and HIV vaccine researchers together to share data and discuss strategies to move both fields forward.
Click here for information on CRI's other past symposia.
CRI programs also encompass fundraising events, which directly support scientific research initiatives, as well as educational lectures for donors, the media, cancer patients, and the public.